DOCSLIB.ORG

Compliance Officers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compliance Officers Compliance Officers Organization Representative Title Email Phone AbbVie Inc. Karen Hale Vice President, Chief Ethics & Compliance Officer [email protected] 847-932-7850 Amgen Inc. Cynthia Patton Senior Vice President, Chief Compliance Officer [email protected] 805-447-6217 Anacor Pharmaceuticals, Inc. Ryan T. Sullivan Senior Vice President and General Counsel [email protected] 650-543-7500 Astellas Pharma US, LLC Nahrin Marino Vice President, Head of Ethics & Compliance [email protected] 224-205-5618 Americas AstraZeneca LP Trudy Tan Vice President Compliance, North America [email protected] 302-885-5692 Bayer Corporation Lawrence Platkin Vice President and Compliance Officer [email protected] 973-305-5439 Biogen F. Ty Edmondson Chief Compliance & International Counsel [email protected] Boehringer Ingelheim Joshua Marks Chief Ethics and Compliance Officer [email protected] Pharmaceuticals, Inc. Bristol-Myers Squibb Company Adam Dubow Chief Compliance and Ethics Officer [email protected] 609-252-3034 Celgene Corporation Maria E. Pasquale EVP and Chief Compliance Officer [email protected] 908-673-9757 Cell Therapeutics, Inc. Steven E. Benner, M.D. Executive Vice President & Chief Medical Officer [email protected] 206-272-4652 Corcept Therapeutics Inc. G. Charles Robb Chief Financial Officer / Compliance Officer [email protected] 650-688-8783 Cumberland Pharmaceuticals James Herman Corporate Compliance Officer [email protected] 615-255-0068 Inc. Daiichi Sankyo, Inc. Matt Allegrucci Vice President, Chief Ethics & Compliance Officer [email protected] 908-992-6674 Eisai Inc. Vincent P. Andrews Vice President, General Counsel and Chief [email protected] 201-746-2938 Compliance Officer Senior Vice President ERM and Chief Compliance Melissa Stapleton Eli Lilly and Company Officer [email protected] 317-276-2923 Barnes EMD Serono, Inc. Brian C. Barry Chief Compliance Officer and Compliance Counsel [email protected] 781-681-2008 Executive Vice President & Chief Compliance Officer, Endo Pharmaceuticals Inc. Jon Smollen Corporate Compliance & Business Practices [email protected] 610-387-6811 Executive Vice President, General Counsel & Exelixis, Inc. Pamela Simonton Chief Compliance Officer [email protected] 650-225-3562 Senior Vice President, Secretary and Chief Genentech, Inc. Sean Johnston Compliance Officer, Head of Legal Affairs, North [email protected] 650-467-2160 America Genzyme Corporation Shannon Kelly Head of North America Ethics and Business Integrity [email protected] 617-768-6852 Vice President & Compliance Officer, North America GlaxoSmithKline Michael L. Shaw Pharmaceuticals [email protected] 215-751-7337 Executive Vice President, General Counsel and Chief Grifols, Inc. David Bell Compliance Officer [email protected] 323-227-7540 Horizon Pharma Timothy Ayers Vice President, Chief Compliance Officer [email protected] 224.383.3210 SVP, Associate General Counsel & Chief Compliance Jazz Pharmaceuticals, Inc. Robert McKague Officer [email protected] 650-492-0938 Johnson & Johnson Vice President Health Care Compliance, (Pharmaceutical Sujata Dayal Pharmaceuticals [email protected] Companies) LEO Pharma Inc. Keith Bernius U.S. Chief Financial Officer & VP Business [email protected] 973-637-1690 Operations; Chief Compliance Officer Lundbeck LLC Tom Forrestor Vice President, US Legal Affairs & General Counsel [email protected] Mallinckrodt Pharmaceuticals Karen P. Sheehy Senior Vice President & Chief Compliance Officer [email protected] 908-238-6326 Last Updated 5/30/2019 Compliance Officers Executive Vice President, Legal Affairs, M & A, General Counsel and Corporate Compliance Officer Marathon Pharmaceuticals, LLC Patrick J. Morris [email protected] 224-515-3402 Medivation Inc. Jennifer J. Rhodes General Counsel and Chief Compliance Officer [email protected] 415-432-6721 Senior Vice President and Chief Ethics & Compliance Merck & Co., Inc. Ashley Watson Officer [email protected] 908-740-4408 Vice President, Deputy General Counsel and Chief Millennium Pharmaceuticals, Elizabeth A. Lewis Compliance Officer [email protected] 617-444-1693 Inc. Novartis Pharmaceuticals Vice President, Ethics & Compliance; Chief Bryant Aaron [email protected] Corporation Compliance Officer Noven Pharmaceuticals, Inc. Elysa Mantel Corporate Counsel [email protected] Novo Nordisk, Inc. Frank Bigley, PhD, Esq. Chief Compliance Officer [email protected] 609-987-5428 Otsuka America Pharmaceutical, Jennifer H. McGee, Esq. Chief Compliance Officer [email protected] 240-683-3351 Inc. (OAPI) Pfizer Inc Rady Johnson Chief Compliance and Risk Officer [email protected] Purdue Pharma L.P. Bert Weinstein Vice President, Corporate Compliance [email protected] 203-588-8288 Regeneron Pharmaceuticals, Inc. Beth F. Levine Chief Compliance Officer [email protected] 914-785-3096 Sanofi US Shannon Kelley Head of US Ethics & Business Integrity [email protected] 617-768-6852 Senior Vice President, General Counsel and Chief Sentynl Therapeutics, Inc Michael Hercz Compliance Officer [email protected] 858-433-5355 Shionogi Inc. Joseph Spagnardi EVP, Legal & Compliance [email protected] 973-307-3370 Senior Vice President, Chief Compliance and Risk Shire Pharmaceuticals, LLC Caroline H. West Officer [email protected] 484-595-8808 Sigma-Tau Pharmaceuticals, Inc. David Sandoval Director of Legal Affairs & Chief Compliance Officer [email protected] 301-948-1041 Vice President of Regulatory Affairs and Acting Solstice Neurosciences, Inc. Paul Nemeth Compliance Officer [email protected] 267-620-8030 Senior Vice President, General Counsel & Corporate Sucampo Thompas Knapp Secretary [email protected] 301-961-3400 Senior Vice President, Chief Compliance and Ethics Sunovion Pharmaceuticals Inc. Matthew D'Ambrosio Officer [email protected] 508-787-4167 Head of Ethics & Compliance, Global Oncology Takeda Pharmaceutical U.S.A., Latarsha Stewart Business Unit [email protected] 617-551-4941 Inc. Global Ethics & Compliance Office Theravance, Inc. Bradford J. Shafer Senior Vice President & General Counsel [email protected] 650-808-6000 UCB, Inc. Clive Davis VP & Chief Compliance Officer USA [email protected] 770-970-8372 XenoPort, Inc. Tanya Ivanov Compliance Officer, Corporate Counsel [email protected] 408-616-7200 Zogenix, Inc. Steven A. Johnson Compliance Officer [email protected] 866-964-3649 Last Updated 5/30/2019.
Load more

Recommended publications
  • GDH Ltd. MD&A 12/31/2020
    Galaxy Digital Holdings Ltd. Management’s Discussion and Analysis March 29, 2021 Introduction This Management’s Discussion and Analysis (“MD&A”), dated March 29, 2021, relates to the financial condition and results of operations of Galaxy Digital Holdings Ltd. (“GDH Ltd.” or together with its consolidated subsidiary, the “Company”) as of March 29, 2021, and is intended to supplement and complement the Company’s consolidated financial statements for the year ended December 31, 2020. The Company's only significant asset is a minority interest in Galaxy Digital Holdings LP ("GDH LP" or the "Partnership"), an operating partnership that is building a diversified financial services and investment management business in the cryptocurrency and blockchain space (See Transaction section). GDH LP has separately filed its consolidated financial statements and MD&A for the year ended December 31, 2020, which are available on the Company's SEDAR profile at www.sedar.com. The Company's MD&A should be read in conjunction with GDH LP's consolidated financial statements and MD&A. The Company has included GDH LP's MD&A as an appendix to this MD&A. This MD&A, when read in conjunction with GDH LP's MD&A, was written to comply with the requirements of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”). The consolidated financial statements and MD&A are presented in US dollars, unless otherwise noted and have been prepared in accordance with International Financial Reporting Standards (“IFRS”). In the opinion of management, all adjustments (which consist only of normal recurring adjustments) considered necessary for a fair presentation have been included.
    [Show full text]
  • Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials
    02-DIJ42(4) 2348.qxd 6/9/08 1:46 PM Page 303 STATISTICS 303 Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials Craig H. Mallinckrodt, PhD Research Advisor, Lilly This position paper summarizes relevant theo- simple methods in favor of joint analysis of Research Laboratories, Eli ry and current practice regarding the analysis data from all time points based on a multivari- Lilly and Company, of longitudinal clinical trials intended to sup- ate model (eg, of a mixed-effects type). One Indianapolis, Indiana port regulatory approval of medicinal prod- such newer method, a likelihood-based mixed- Peter W. Lane, MA, CStat ucts, and it reviews published research regard- effects model repeated measures (MMRM) ap- Director of Consultancy and Training, Research Statistics ing methods for handling missing data. It is proach, has received considerable attention in Unit, GlaxoSmithKline, one strand of the PhRMA initiative to improve the clinical trials literature. We discuss specif- Harlow, United Kingdom efficiency of late-stage clinical research and ic concerns raised by regulatory agencies with Dan Schnell, PhD gives recommendations from a cross-industry regard to MMRM and review published evi- Section Head, Pharmaceutical Statistics, team. We concentrate specifically on continu- dence comparing LOCF and MMRM in terms Procter & Gamble ous response measures analyzed using a linear of validity, bias, power, and type I error. Our Pharmaceuticals, model, when the goal is to estimate and test main conclusion is that the mixed model ap- Mason, Ohio treatment differences at a given time point. proach is more efficient and reliable as a Yahong Peng, PhD Traditionally, the primary analysis of such tri- method of primary analysis, and should be Senior Biometrician, Clinical Biostatistics, Merck als handled missing data by simple imputation preferred to the inherently biased and statisti- Research Lab, Upper using the last, or baseline, observation carried cally invalid simple imputation approaches.
    [Show full text]
  • Endo Pharmaceuticals Inc. V. Actavis
    United States Court of Appeals for the Federal Circuit ______________________ ENDO PHARMACEUTICALS INC., MALLINCKRODT LLC, Plaintiffs-Appellees v. ACTAVIS LLC, FKA ACTAVIS INC., ACTAVIS SOUTH ATLANTIC LLC, TEVA PHARMACEUTICALS USA, INC., Defendants-Appellants ______________________ 2018-1054 ______________________ Appeal from the United States District Court for the District of Delaware in No. 1:14-cv-01381-RGA, Judge Richard G. Andrews. ______________________ Decided: May 3, 2019 ______________________ MARTIN JAY BLACK, Dechert LLP, Philadelphia, PA, ar- gued for plaintiffs-appellees. Also represented by SHARON K. GAGLIARDI; BLAKE GREENE, Austin, TX; JONATHAN LOEB, Mountain View, CA; ROBERT RHOAD, Princeton, NJ. JEFFREY J. TONEY, Kasowitz, Benson, Torres & Fried- man LLP, Atlanta, GA, for plaintiff-appellee Mallinckrodt LLC. Also represented by RODNEY R. MILLER, PAUL GUNTER WILLIAMS. 2 ENDO PHARM. INC. v. ACTAVIS LLC JOHN C. O'QUINN, Kirkland & Ellis LLP, Washington, DC, argued for defendants-appellants. Also represented by WILLIAM H. BURGESS; CHARLES A. WEISS, ERIC H. YECIES, Holland & Knight, LLP, New York, NY. ______________________ Before WALLACH, CLEVENGER, and STOLL, Circuit Judges. Opinion for the court filed by Circuit Judge WALLACH. Dissenting opinion filed by Circuit Judge STOLL. WALLACH, Circuit Judge. Appellees Endo Pharmaceuticals Inc. (“Endo Pharma- ceuticals”) and Mallinckrodt LLC (“Mallinckrodt”) (collec- tively, “Endo”) sued Appellants Actavis LLC, Actavis South Atlantic LLC, and Teva Pharmaceuticals USA, Inc. (collec- tively, “Actavis”) in the U.S. District Court for the District of Delaware (“District Court”), alleging that two Abbrevi- ated New Drug Applications filed by Actavis infringed claims 1–6 (“the Asserted Claims”) of Mallinckrodt’s U.S. Patent No. 8,871,779 (“the ’779 patent”), which Endo Phar- maceuticals licenses.
    [Show full text]
  • Notice of EGM-Signed
    NOTICE IS HEREBY GIVEN THAT THE EXTRAORDINARY GENERAL MEETING (SERIAL NO.: 1/2021-22) OF THE MEMBERS OF ANVITI INSURANCE BROKERS PRIVATE LIMITED WILL BE HELD ON 23rd May, 2021, AT 5 P.M. THROUGH VIDEO CONFERENCING (“VC”) TO TRANSACT THE FOLLOWING BUSINESS: Special Business: 1. To approve change in name of the Company and consequent amendment in Memorandum and Articles of Association of the Company: To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution: RESOLVED THAT pursuant to the provisions of section 13(2), section 14 and other applicable provisions of the Companies Act, 2013 read with relevant rules made thereunder (including any statutory modification(s) or re-enactments thereof for the time being in force) and subject to the approval of the Registrar of Companies, consent of the shareholders be and is hereby accorded to change the name of the Company from ‘Anviti Insurance Brokers Private Limited’ to ‘Aon India Insurance Brokers Private Limited’ and consequently the Memorandum of Association of the Company be and is hereby altered by substituting the following Clause for existing Clause 1 thereof:. “The name of the Company is Aon India Insurance Brokers Private Limited.” RESOLVED FURTHER THAT the name “Anviti Insurance Brokers Private Limited” wherever appearing in Memorandum and Articles of Association and other documents and papers of the Company be substituted by the name “Aon India Insurance Brokers Private Limited” upon approval of the same by the Registrar of Companies. RESOLVED FURTHER THAT Directors, Chief Executive Officer, Chief Compliance Officer & General Counsel, be and are hereby severally and/or jointly be authorised to do all such acts and deeds as may be required to give effect to the resolution, including signing, verifying, executing and filing all necessary forms, agreements and documents with any Governmental authority including but not limited to, the Insurance Regulatory and Development Authority of India, the Registrar of Companies/Ministry of Corporate Affairs.
    [Show full text]
  • Amgen Inc. V. Sanofi, No
    No. IN THE Supreme Court of the United States ———— AMGEN INC., AMGEN MANUFACTURING LIMITED, AND AMGEN USA, INC., Petitioners, v. SANOFI, AVENTISUB LLC, REGENERON PHARMACEUTICALS INC., AND SANOFI-AVENTIS U.S., LLC, Respondents. ———— On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit ———— PETITION FOR A WRIT OF CERTIORARI ———— STUART L. WATT JEFFREY A. LAMKEN WENDY A. WHITEFORD Counsel of Record ERICA S. OLSON MICHAEL G. PATTILLO, JR. EMILY C. JOHNSON SARAH J. NEWMAN AMGEN INC. MOLOLAMKEN LLP One Amgen Center Drive The Watergate, Suite 660 Thousand Oaks, CA 91320 600 New Hampshire Ave., NW (805) 447-1000 Washington, D.C. 20037 (202) 556-2000 [email protected] Counsel for Petitioners :,/621(3(635,17,1*&2,1&± ±:$6+,1*721'& QUESTION PRESENTED The 1952 Patent Act requires patents to “contain a written description of the invention, and of the manner and process of making and using it.” 35 U.S.C. §112(a). The “written description” must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” Ibid. “The object of the statute is to require the patentee to describe his invention so that others may construct and use it after the expiration of the patent.” Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47, 57 (1938). The Federal Circuit has construed §112(a) as impos- ing separate “written description” and “enablement” re- quirements subject to different standards.
    [Show full text]
  • ANTI-CORRUPTION Quarterly
    ANTI-CORRUPTION Quarterly 2nd Quarter 2015 IN THIS ISSUE: FCPA IMPLICATIONS OF RECENT DODD-FRANK WHISTLEBLOWER AWARDS FEATURES Under the Dodd-Frank Act, whistleblowers who provide information that helps the SEC recover money for violations of federal securities laws—including FCPA IMPLICATIONS OF RECENT the FCPA—can receive as much as 30 percent of the amount recovered. This DODD-FRANK WHISTLEBLOWER whistleblower bounty creates a strong financial incentive to report potential AWARDS ............................................ 1 violations. Recent whistleblower awards show just how strong that incentive is. And the rise in whistleblower tips related to potential FCPA violations, IMPACT OF THE CURRENT FIFA SCANDAL: DOJ TARGETS combined with an increase in awards to individuals abroad, suggests that the INTERNATIONAL CORRUPTION whistleblower provision is likely to have an increasing influence on corporate BEYOND THE FCPA ......................... 1 FCPA compliance. CONTINUED ON PAGE 4 COLUMNS GLOBAL WATCH ............................... 1 IMPACT OF THE CURRENT FIFA SCANDAL: DOJ TARGETS INTERNATIONAL CORRUPTION BEYOND THE FCPA IN THE INTERIM ................................ 2 On May 27, 2015, the Department of Justice announced an indictment against nine high-ranking Fédération Internationale de Football Association (FIFA) COMPLIANCE CORNER: officials and five corporate executives on corruption charges. The 164-page COMPLIANCE OFFICERS BEWARE: INDIVIDUALS PAYING THE PRICE indictment alleges that the defendants took advantage of their positions in UNDER THE FCPA AND NON-U.S. organized soccer to unlawfully enrich themselves. While none of the current ANTI-CORRUPTION LAWS .............. 4 allegations gives rise to an FCPA violation, the FIFA indictment, together with other recent enforcement actions against Goodyear Tire & Rubber Company OF NOTE ........................................... 8 and Diebold, Inc., demonstrates that federal prosecutors are pursuing aggressively all forms of corrupt payments, not just those that violate the FCPA.
    [Show full text]
  • Driving Awareness and Action Around the Country's
    THANKS DRIVING TO AWARENESS ALL OUR DONORS AND ACTION AROUND THE COUNTRY’S OPIOID CRISIS $500,000 and over Leon D. Black Sonenshine Partners Human Services (Birmingham, MI) Google Bostock Family Foundation Sovereign Health of California Ibra Morales Conrad N. Hilton Foundation The Boucher Charitable Foundation Partnership for a Drug-Free Wash- National Association of Broadcast- Bristol-Myers Squibb Foundation, Inc. ington (Lacey, WA) ers $250,000-$499,999 Timothy J. Brosnan Staten Island Partnership for Com- Gordon Ogden Consumer Healthcare Products Craig D. Brown munity Wellness (Staten Island, NY) Pascack Valley High School Association The Bruni Foundation Televisa, S.A. de C.V. George Patterson CVS Health Cleary Gottlieb Steen & Hamilton, LLP Truth Initiative PepsiCo, Inc. Jazz Pharmaceuticals Corning Incorporated Foundation Turn 2 Foundation Donald K. Peterson Major League Baseball The Council on Alcohol & Drug Turner Broadcasting Systems, Inc. Thomas Reuters Mallinckrodt Pharmaceuticals Abuse (Dallas, TX) Venable LLP Tamara Robinson Pharmaceutical Research & The Marvin H. Davidson Foundation Robert Wood Johnson Foundation Marc Rosenbaum Manufacturers of America Inc. The Xerox Foundation Mitchell S. Rosenthal, M.D. Purdue Pharma L.P. Deloitte Services LLP Rye City School District Discovery Communications $1,000-$4,999 Andrew Scott $100,000-$249,999 DrugFreeAZKids.org (Phoenix, AZ) All Filters, LLC Jeff Shiver James E. & Diane W. Burke Fox Broadcasting Company Bill Anderson Roberto Simon Foundation Joan Ganz Cooney AOL, Inc. Simulmedia, Inc. Millenium Health, LLC General Electric Company Auburn Pharmaceutical Yvette A. Smith Pfizer Inc. The Gottesman Fund The Ayco Company, LP Karen Spence Wachtell, Lipton, Rosen & Katz The Governor’s Prevention Partner- Bob Bailey Allan Spivack ship (Wethersfield, CT) Bernstein Investment Research & State of Maine Department of $25,000-$99,999 Hawaii Meth Project Management Health and Human Services Alkermes HBO C.R.
    [Show full text]
  • Bylaws of Infx Sdr, Inc. a Delaware Corporation
    BYLAWS OF INFX SDR, INC. A DELAWARE CORPORATION TABLE OF CONTENTS ARTICLE I OFFICES AND AGENTS Section 1. PRINCIPAL EXECUTIVE OFFICE AND REGISTERED OFFICE Section 2. OTHER OFFICES Section 3. REGISTERED AGENTS AND REGISTERED OFFICES ARTICLE II DIRECTORS - MANAGEMENT Section 1. RESPONSIBILITY OF BOARD OF DIRECTORS Section 2. NUMBER AND QUALIFICATION OF DIRECTORS Section 3. ELECTION, CUMULATIVE VOTING AND TERM OF OFFICE OF DIRECTORS Section 4. VACANCIES IN THE BOARD Section 5. REMOVAL OF DIRECTORS Section 6. COMPENSATION OF DIRECTORS Section 7. COMMITTEES OF THE BOARD AND APPOINTMENT TO COMMITTEE Section 8. RESIGNATIONS OF A DIRECTOR ARTICLE III MEETINGS OF DIRECTORS Section 1. ANNUAL MEETINGS OF DIRECTORS Section 2. OTHER REGULAR MEETINGS OF DIRECTORS Section 3. NOTICE OF ANNUAL AND OTHER REGULAR MEETINGS OF DIRECTORS Section 4. SPECIAL MEETINGS OF DIRECTORS AND REQUIRED NOTICES Section 5. NOTICE OF ADJOURNMENT OF MEETINGS Section 6. WAIVER OR LACK OF NOTICE OF MEETING OF DIRECTORS Section 7. DIRECTORS ACTION WITHOUT MEETING Section 8. QUORUM FOR MEETINGS OF DIRECTORS Section 9. EFFECT IF ONLY A SOLE DIRECTOR IS REQUIRED Section 10 ELECTRONIC PARTICIPATION IN MEETINGS OF DIRECTORS ARTICLE IV OFFICERS - MANAGEMENT Section 1. OFFICERS Section 2. ELECTION OF OFFICERS Section 3. SUBORDINATE OFFICERS Section 4. REMOVAL AND RESIGNATION OF OFFICERS Section 5. VACANCIES IN AN OFFICE Section 6. CHAIRMAN OF THE BOARD Section 7. PRESIDENT Section 8. VICE PRESIDENT Section 9. SECRETARY Section 10. CHIEF FINANCIAL OFFICER Section 11. CHIEF COMPLIANCE OFFICER Section 12. GENERAL COUNSEL i ARTICLE V MEETINGS OF SHAREHOLDERS Section 1. PLACE OF MEETINGS Section 2. ANNUAL MEETINGS OF SHAREHOLDERS Section 3.
    [Show full text]
  • Event Sessions
    Pre-Conference Training Sunday 9/26 8:00AM-9:00AM CAMS Examination Preparation Seminar and Workshop A Check-in (Separate registration required.) 8:00AM-7:30PM Main Conference Registration Desk Open Bags, Lanyards and Badges courtesy of AI Oasis 9:00AM-5:00PM CAMS Examination Preparation Seminar Led by CAMS-certified instructors, the CAMS Examination Preparation Seminar reviews critical information in an easy-to-follow format that prepares you to sit for the CAMS Examination. Benefit from this interactive study session as AML experts walk you through core content areas and practice questions. To register for a live-preparation seminar please contact [email protected]. Instructor: Peter D. Wild, FCA, CAMS-Audit, Founder, Wild AML Solutions LLC 9:00AM-12:00PM Workshop A: SAR Case Study: From Suspicion to Conviction Filing SARs is a cornerstone of successful AFC programs, but compliance professionals often know much less about what comes after that. In this interactive workshop, our experts will take attendees through the many paths a SAR may take— from editing the narrative to working with law enforcement following up on the lead. Group exercises may include everything from simulating depositions to assuming the role of grand juror considering evidence. Join this comprehensive and expert-led workshop to follow the paths of SARs as they play their lead role in the AFC universe. Key Areas Covered • Standardizing SAR protocols in areas such as alert responses, investigation/documentation and filing decision-making to ensure clarity and
    [Show full text]
  • Compliance Officers.Xlsx
    Compliance Officers.xlsx Organization Representative Title Email Phone AbbVie Inc. Karen Hale Vice President, Chief Ethics & Compliance Officer [email protected] 847-932-7850 Amgen Inc. Cynthia Patton Senior Vice President, Chief Compliance Officer [email protected] 805-447-6217 Anacor Pharmaceuticals, Inc. Ryan T. Sullivan Senior Vice President and General Counsel [email protected] 650-543-7500 Astellas Pharma US, LLC Nahrin Marino Vice President, Head of Ethics & Compliance [email protected] 224-205-5618 Americas AstraZeneca LP Trudy Tan Vice President Compliance, North America [email protected] 302-885-5692 Bayer Corporation Lawrence Platkin Vice President and Compliance Officer [email protected] 973-305-5439 Biogen Soph Sophocles Chief Compliance Officer [email protected] 781-464-1943 Boehringer Ingelheim Joshua Marks Chief Ethics and Compliance Officer [email protected] Pharmaceuticals, Inc. Bristol-Myers Squibb Company Adam Dubow Chief Compliance and Ethics Officer [email protected] 609-252-3034 Celgene Corporation Maria E. Pasquale EVP and Chief Compliance Officer [email protected] 908-673-9757 Cell Therapeutics, Inc. Steven E. Benner, M.D. Executive Vice President & Chief Medical Officer [email protected] 206-272-4652 Corcept Therapeutics Inc. G. Charles Robb Chief Financial Officer / Compliance Officer [email protected] 650-688-8783 Cumberland Pharmaceuticals James Herman Corporate Compliance Officer [email protected] 615-255-0068 Inc. Daiichi Sankyo, Inc. Matt Allegrucci Vice President, Chief Ethics & Compliance Officer [email protected] 908-992-6674 Eisai Inc. Vincent P. Andrews Vice President, General Counsel and Chief [email protected] 201-746-2938 Compliance Officer Senior Vice President ERM and Chief Compliance Melissa Stapleton Eli Lilly and Company Officer [email protected] 317-276-2923 Barnes EMD Serono, Inc.
    [Show full text]
  • An Integrated Approach to Corporate Compliance: a Resource for Health Care Boards of Directors
    United States Department of Health and Human Services Office of Inspector General American Health Lawyers Association Acknowledgement This educational resource is the second collaborative document drafted by representatives of the American Health Lawyers Association and the Office of Inspector General of the United States Department of Health and Human Services. This publication would not have been possible without the dedicated effort of numerous individuals at both organizations. It is intended to be a useful resource for those serving on the Boards of Directors of our nation’s health care institutions. Special recognition and thanks go to those serving on the drafting task force for this document: Jane Reister Conard, Senior Counsel, Intermountain Health Care, Inc. Douglas A. Hastings, Epstein Becker & Green PC Michael C. Hemsley, General Counsel and Vice President, Corporate Compliance, Catholic Health East Lewis M. Morris, Chief Counsel for the Inspector General of the United States Department of Health and Human Services Michael W. Peregrine, McDermott Will & Emery The authors are grateful to the American Health Lawyers Association for compiling the results of the survey included as Attachment A. They also wish to express sincere thanks to Mary Boutsikaris of the American Health Lawyers Association for her design work on this publication. Released July 1, 2004 I. Introduction s a supplement to the publication last year of Corporate Responsibility and Corporate Compliance: A Resource for Health Care Boards of Directors,1 (“Corporate Responsibility and Corporate Compliance”), a A joint educational effort of the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) and the American Health Lawyers Association (“AHLA”), this document addresses the roles of the in-house corporate general counsel (“General Counsel”) and an organization’s Chief Compliance Officer in supporting the compliance oversight function of health care organization governing boards (“Boards of Directors” or “Boards”).
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]